Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Interventions: ATI-045, Placebo; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 53
States / cities: Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 47 more

Conditions: Advanced Cancer, Metastatic Cancer, Breast Cancer
Interventions: ART4215, Talazoparib, Niraparib; Drug
Lead sponsor: Artios Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: New Haven, Connecticut • Orlando, Florida • New York, New York + 4 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Lirentelimab (AK002), Placebo; Drug · Other
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 51
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 44 more

Conditions: Polycystic Ovary Syndrome, PCOS
Interventions: Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT); Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hereditary Angioedema Types I and II
Interventions: C1-esterase inhibitor - single intravenous dose, C1-esterase inhibitor - subcutaneous low dose, C1-esterase inhibitor - subcutaneous medium dose, C1-esterase inhibitor - subcutaneous high dose; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 5
States / cities: Atlanta, Georgia • Chevy Chase, Maryland • Cincinnati, Ohio + 2 more

Conditions: Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
Interventions: Canakinumab (ACZ885); Drug
Lead sponsor: Novartis; Industry
Eligibility: 3 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 3 more

Conditions: Dermatitis, Atopic, Dermatitis Eczema, Dermatitis, Eczematous
Interventions: ASN002, Placebo Oral Tablet; Drug
Lead sponsor: Asana BioSciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 9
States / cities: Fremont, California • Los Angeles, California • San Diego, California + 5 more

Conditions: Acute Hereditary Angio Edema
Interventions: OCTA-C1-INH, Placebo; Drug · Other
Lead sponsor: Octapharma; Industry
Eligibility: 2 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio

Conditions: Atopic Dermatitis
Interventions: Fluocinonide cream; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: North Little Rock, Arkansas • Redwood City, California • Rolling Hills Estates, California + 5 more

Conditions: Breast Cancer
Interventions: Exemestane, Fulvestrant; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Dermatitis Atopic
Interventions: Dupilumab (SAR231893); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida • East Windsor, New Jersey

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus, Topical corticosteroids; Drug
Lead sponsor: MEDA Pharma GmbH & Co. KG; Industry
Eligibility: 3 Months to 12 Months
Enrollment: 2,418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 30
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more

Conditions: Peanut Allergy
Interventions: Peanut in diet; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 4 Months to 11 Months
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Atopic Dermatitis, Eczema, Healthy
Interventions: GENEActiv Accelerometry Device, Centrepoint Insights Watch (CPIW) Accelerometry Device, Apple Watch Accelerometry Device, Polysomnography, Videography; Device
Lead sponsor: SymmetryScience Group, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Spinal Cord Injury, Pressure Ulcers
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 79 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hereditary Angioedema (HAE)
Interventions: DX-2930, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Atopic Dermatitis
Interventions: Routine Care/Education, Psychoeducation/Coping Prevention; Other · Behavioral
Lead sponsor: Seton Healthcare Family; Other
Eligibility: 2 Months to 12 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypersensitivity
Interventions: Butenafine HCl 1% (BAY1896425), Positive Control-Sodium lauryl sulfate (SLS), Negative Control; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Fairfield, New Jersey

Conditions: Atopic Dermatitis
Interventions: BMX-010, Placebo; Drug
Lead sponsor: BioMimetix JV, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 19
States / cities: Birmingham, Alabama • Bryant, Arkansas • Fort Smith, Arkansas + 16 more

Conditions: Atopic Dermatitis, Alopecia Areata
Interventions: Abrocitinib; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 12 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: Crisaborole, Scratch sensor; Drug · Device
Lead sponsor: Northwestern University; Other
Eligibility: 2 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hereditary Angioedema (HAE)
Interventions: CINRYZE 500, CINRYZE 1000; Biological
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Colorado Springs, Colorado • Las Vegas, Nevada • Eugene, Oregon

Conditions: Allergic Skin Reaction
Interventions: Hyaluronidase, Histamine, Saline; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 253 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 5
States / cities: Eugene, Oregon • Lake Oswego, Oregon • Portland, Oregon + 2 more

Search by objective public record fields.

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

Insulin Differences Between African-American and Caucasian Female Adolescents With Polycystic Ovary Syndrome (PCOS)

A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis

SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"

Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Early Peanut Introduction: Translation to Clinical Practice

Atopic Dermatitis With Accelerometry and Polysomnography (ADAP)

Skin Blood Flow Response to Insulin Iontophoresis in Pressure Ulcers of SCI

A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

A Psychoeducational Prevention for the Treatment of Atopic Dermatitis in Youth and Their Families

Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)

A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis

Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema

Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)